Fintel reports that on October 2, 2023, Needham reiterated coverage of Esperion Therapeutics (NASDAQ:ESPR) with a Buy recommendation.
Analyst Price Forecast Suggests 969.73% Upside
As of August 31, 2023, the average one-year price target for Esperion Therapeutics is 10.48. The forecasts range from a low of 2.02 to a high of $23.10. The average price target represents an increase of 969.73% from its latest reported closing price of 0.98.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Esperion Therapeutics is 168MM, an increase of 91.00%. The projected annual non-GAAP EPS is -2.48.
What is the Fund Sentiment?
There are 205 funds or institutions reporting positions in Esperion Therapeutics. This is a decrease of 99 owner(s) or 32.57% in the last quarter. Average portfolio weight of all funds dedicated to ESPR is 0.04%, an increase of 5.88%. Total shares owned by institutions decreased in the last three months by 8.24% to 75,259K shares. 
The put/call ratio of ESPR is 0.09, indicating a bullish outlook.
What are Other Shareholders Doing?
Wasatch Advisors holds 13,140K shares representing 12.28% ownership of the company. In it's prior filing, the firm reported owning 13,354K shares, representing a decrease of 1.63%. The firm decreased its portfolio allocation in ESPR by 16.35% over the last quarter.
Armistice Capital holds 9,193K shares representing 8.59% ownership of the company. In it's prior filing, the firm reported owning 3,679K shares, representing an increase of 59.98%. The firm increased its portfolio allocation in ESPR by 119.49% over the last quarter.
Point72 Asset Management holds 4,975K shares representing 4.65% ownership of the company. In it's prior filing, the firm reported owning 3,600K shares, representing an increase of 27.64%. The firm increased its portfolio allocation in ESPR by 16.00% over the last quarter.
Meditor Group holds 4,403K shares representing 4.12% ownership of the company. No change in the last quarter.
Bellevue Group holds 4,208K shares representing 3.93% ownership of the company. No change in the last quarter.
Esperion Therapeutics Background Information
(This description is provided by the company.)
Through scientific and clinical excellence, and a deep understanding of cholesterol biology, the experienced Lipid Management Team at Esperion is committed to developing new LDL-C lowering medicines that will make a substantial impact on reducing global cardiovascular disease, the leading cause of death around the world.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
